120 related articles for article (PubMed ID: 8477092)
1. Serotonergic mechanisms are involved in the hemostatic action of erythropoietin in uremic patients.
Malyszko J; Mazerska M; Malyszko J; Pawlak K; Azzadin A; Mysliwiec M; Buczko W
Int J Clin Lab Res; 1993; 23(1):42-4. PubMed ID: 8477092
[TBL] [Abstract][Full Text] [Related]
2. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy.
Malyszko J; Malyszko JS; Borawski J; Rydzewski A; Kalinowski M; Azzadin A; Mysliwiec M; Buczko W
Thromb Res; 1995 Jan; 77(2):133-43. PubMed ID: 7740505
[TBL] [Abstract][Full Text] [Related]
3. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN
Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of erythropoietin on platelet serotonin storage and platelet aggregation in hemodialysis patients with reference to ketanserin treatment.
Borawski J; Rydzewski A; Pawlak K; Azzadin A; Buczko W; Mysliwiec M
Thromb Res; 1998 May; 90(4):171-80. PubMed ID: 9692616
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin and uremic platelet aggregation in vivo and in vitro.
Malyszko JS; Malyszko J; Pawlak K; Mysliwiec M
Int J Clin Lab Res; 1996; 26(3):199-202. PubMed ID: 8905452
[TBL] [Abstract][Full Text] [Related]
6. [Possible role of serotonin in hemostatic the mechanism of action of desmopressin (DDAVP) in patients with uremia].
Małyszko J; Małyszko J; Pietraszek M; Azzadin A; Myśliwiec M; Buczko W
Pol Arch Med Wewn; 1993 Aug; 90(2):105-11. PubMed ID: 8247943
[TBL] [Abstract][Full Text] [Related]
7. The effect of recombinant human erythropoietin on hemostasis, fibrinolysis, and blood rheology in autologous blood donors.
Biesma DH; Bronkhorst PJ; de Groot PG; van de Wiel A; Kraaijenhagen RJ; Marx JJ
J Lab Clin Med; 1994 Jul; 124(1):42-7. PubMed ID: 8035101
[TBL] [Abstract][Full Text] [Related]
8. Effects of recombinant human erythropoietin and correction of anemia on platelet function in hemodialysis patients.
Akizawa T; Kinugasa E; Kitaoka T; Koshikawa S
Nephron; 1991; 58(4):400-6. PubMed ID: 1922603
[TBL] [Abstract][Full Text] [Related]
9. Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin.
Małyszko JS; Małyszko J; Pawlak K; Pawlak D; Buczko W; Myśliwiec M
Nephron; 2000 Apr; 84(4):305-11. PubMed ID: 10754406
[TBL] [Abstract][Full Text] [Related]
10. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma.
Zwaginga JJ; IJsseldijk MJ; de Groot PG; Kooistra M; Vos J; van Es A; Koomans HA; Struyvenberg A; Sixma JJ
Thromb Haemost; 1991 Dec; 66(6):638-47. PubMed ID: 1665596
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin to correct uremic bleeding.
Viganò G; Benigni A; Mendogni D; Mingardi G; Mecca G; Remuzzi G
Am J Kidney Dis; 1991 Jul; 18(1):44-9. PubMed ID: 2063854
[TBL] [Abstract][Full Text] [Related]
12. Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients.
Huraib S; al-Momen AK; Gader AM; Mitwalli A; Sulimani F; Abu-Aisha H
Clin Nephrol; 1991 Nov; 36(5):252-7. PubMed ID: 1752076
[TBL] [Abstract][Full Text] [Related]
13. Some aspects of hemostasis in CAPD patients treated with erythropoietin.
Małyszko J; Suchowierska E; Małyszko JS; Myśliwiec M
Kidney Blood Press Res; 2002; 25(4):240-4. PubMed ID: 12424426
[TBL] [Abstract][Full Text] [Related]
14. Influence of recombinant human erythropoietin on hematological and hemostatic parameters with special reference to microhemolysis.
Maurin N; Fitzner S; Fritz H; Gladziwa U; H agel J; Stefanidis I
Clin Nephrol; 1995 Mar; 43(3):196-200. PubMed ID: 7774078
[TBL] [Abstract][Full Text] [Related]
15. [Effects of the treatment with human recombinant erythropoietin on primary hemostasis in uremic patients].
Cases A; Escolar G; Reverter JC; Garrido M; Ordinas A; López-Pedret J; Castillo R; Revert L
Med Clin (Barc); 1990 Nov; 95(17):644-7. PubMed ID: 2089202
[TBL] [Abstract][Full Text] [Related]
16. The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients.
Wirtz JJ; van Esser JW; Hamulyák K; Leunissen KM; van Hooff JP
Clin Nephrol; 1992 Nov; 38(5):277-82. PubMed ID: 1451341
[TBL] [Abstract][Full Text] [Related]
17. Hemostatic and fibrinolytic response to desmopressin in uremic patients.
Chen KS; Huang CC; Leu ML; Deng P; Lo SK
Blood Purif; 1997; 15(2):84-91. PubMed ID: 9087815
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human erythropoietin treatment improves platelet function in uremic patients.
Cases A; Escolar G; Reverter JC; Ordinas A; Lopez-Pedret J; Revert L; Castillo R
Kidney Int; 1992 Sep; 42(3):668-72. PubMed ID: 1405344
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human erythropoietin increases blood pressure, platelet aggregability and platelet free calcium mobilisation in uraemic children: a possible link?
Van Geet C; Van Damme-Lombaerts R; Vanrusselt M; de Mol A; Proesmans W; Vermylen J
Thromb Haemost; 1990 Aug; 64(1):7-10. PubMed ID: 2274929
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation.
Gordge MP; Leaker B; Patel A; Oviasu E; Cameron JS; Neild GH
Thromb Res; 1990 Jan; 57(2):171-82. PubMed ID: 2315882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
